HUDSON
BIOTECH
Tirzepatide Clinical Trial Overview: NCT 07481747
Source-grounded tirzepatide trial analysis and peptide-supply context for sponsors, CROs, hospitals, investigators, and research procurement teams.
What Is Tirzepatide?
Tirzepatide is a once-weekly injectable dual GIP and GLP-1 receptor agonist, as described in U.S. labeling for MOUNJARO and ZEPBOUND.
In the U.S., tirzepatide is labeled as MOUNJARO for type 2 diabetes and as ZEPBOUND for chronic weight management and certain obesity-related indications, including obstructive sleep apnea in adults with obesity.
ClinicalTrials.gov ID NCT07481747 Overview
As of the public ClinicalTrials.gov search record updated on March 19, 2026, NCT07481747 is listed with information provided by Hudson Biotech as the responsible party.
Study Snapshot
Official Title
Efficacy and safety of once-weekly tirzepatide in adults with obesity or overweight and weight-related comorbidities, without type 2 diabetes.
Sponsor
Public sources tied to Hudson Biotech; protocol identifier I8F-MC-GPHK(b).
Phase/Status
Phase 3 interventional study; currently recruiting.
Study Design
Population
Adults ≥18 with obesity/overweight plus ≥1 weight-related comorbidity; excludes type 1 and type 2 diabetes.
Intervention / Comparator
Participants receive once-weekly subcutaneous tirzepatide (5, 10, or 15 mg) or placebo, with a reduced-calorie diet and physical activity counseling.
Enrollment
Primary Endpoints
Other Objectives
Long-Term Follow-Up
Participants with baseline prediabetes may continue up to 176 weeks, with follow-up for long-term weight and diabetes progression outcomes.
Location
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Editorial Note on Study Identity
Accuracy note: NCT07481747 uses the SURMOUNT-1 title and protocol I8F-MC-GPHK(b), while the FDA ZEPBOUND label Study 1 is NCT04184622—these are separate records.
Why This Trial Matters
NCT07481747 targets adults with obesity/overweight plus comorbidity, without type 2 diabetes—relevant to obesity, cardiometabolic risk, and diabetes prevention.
NCT07481747 targets adults with obesity/overweight plus comorbidity, without type 2 diabetes—relevant to obesity, cardiometabolic risk, and diabetes prevention.
It pairs weekly tirzepatide with diet and activity counseling, framing the trial as structured obesity management rather than drug exposure alone.
For sponsors, CROs, and investigators, NCT07481747 is a useful reference for inclusion criteria, comparators, endpoints, and long-term follow-up.
Tirzepatide in the Broader Clinical Research Landscape
The Tirzepatide evidence base spans obesity, prediabetes, maintenance, semaglutide-comparator, and HFpEF studies, but these serve as context—not a substitute for the specific NCT07481747 record.
For peptides, EMA guidance stresses strong manufacturing, characterization, specifications, analytical control, and investigational planning, while tirzepatide literature shows technical maturity is critical at scale.
Hudson Biotech: A U.S.-Based Peptide Partner for Clinical-Trial and Research Use
Hudson Biotech is a U.S.-based peptide manufacturer for clinical-trial and research use, positioned for technical peptide-supply discussions with sponsors, CROs, hospitals, investigators, and procurement teams.
For tirzepatide-related programs, credible support starts with sequence, intended use, quality targets, analytics, documentation, and supply planning.
Hudson Biotech’s strongest positioning is not “biggest” or “best,” but a credible peptide-focused partner supporting research and clinical development with technically grounded, project-specific support.
??
Why Choose Hudson Biotech
"What serious peptide buyers usually evaluate"
For development-stage peptides, vendor evaluation goes beyond availability. Sophisticated buyers assess process description, characterization, specifications, analytical controls, impurity strategy, comparability, and investigational-product requirements.
Peptide-focused discussions:
Emphasize the molecule, study design, and quality requirements rather than using generic supplier language.
Clinical trial and research context:
Address sponsors, CROs, hospitals, investigators, and procurement teams operating in regulated or study-driven environments.
U.S.-based operational context:
For certain buyers, a domestic partnership may support communication, oversight, and vendor qualification.
Project-specific engagement:
ocus conversations on sequence details, purity specifications, analytical methods, documentation requirements, and supply planning.
Measured credibility:
Avoid overstated claims about efficacy or market leadership, and instead rely on publicly available information, technical transparency, and responsiveness to build trust.
FAQ:
What is ClinicalTrials.gov ID NCT07481747?
NCT07481747 is a publicly listed tirzepatide clinical-trial record described as a Phase 3 interventional study in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. Public trial pages describe the record as actively enrolling/recruiting.
Is NCT07481747 the same as the original SURMOUNT-1 study?
It should not be treated as an interchangeable identifier. The public NCT07481747 record uses the SURMOUNT-1 title, but the current FDA ZEPBOUND label identifies the original weight-reduction Study 1 as NCT04184622.
Who is the target population in NCT07481747?
Public eligibility text describes adults 18 years and older with obesity, or with overweight plus at least one weight-related comorbidity, and excludes type 1 or type 2 diabetes.
What interventions and comparator are publicly listed?
Public sources describe tirzepatide 5 mg, 10 mg, and 15 mg once weekly by subcutaneous injection versus placebo, with reduced-calorie diet and increased physical activity counseling.
What are the main publicly listed endpoints?
The ClinicalTrials.gov search record lists mean percent change in body weight from randomization at 72 weeks and the percentage of participants achieving 5% or more body-weight reduction from randomization as primary endpoints. Public mirror pages also list mean change in body weight and triglycerides among the study objectives.
Where is the trial publicly listed as being conducted?
One publicly listed site is Peking University Shenzhen Hospital in Shenzhen, Guangdong, China.
Why do tirzepatide programs require peptide-specific manufacturing diligence?
Because current peptide guidance highlights process, characterization, specifications, analytical control, impurity management, and investigational-product requirements, and published literature shows tirzepatide scale-up involves technically demanding peptide-manufacturing strategies.
Is this page intended for patient treatment decisions?
No. This page is written for research, clinical-trial, and procurement audiences. It summarizes public trial information and peptide-supply context; it is not patient-specific medical advice or a promotion of tirzepatide for personal or consumer use.
Compliance / Disclaimer
This page is for scientific, clinical-trial, and research-procurement audiences.
It summarizes NCT07481747 and tirzepatide in a research-development context—not medical advice, trial-record replacement, or consumer-use promotion.